Compare Ascendis Pharma A/S (ASND) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Upstart Holdings Inc — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Upstart Holdings Inc trades at $32.54 (market cap $3.13B). The key difference: Ascendis Pharma A/S is far larger — about 5.7× Upstart Holdings Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ASND | UPST | |
|---|---|---|
Market Cap | $17.74B | $3.13B |
Sector | Health | Financials |
52-Week High | $277.18 | $84.13 |
52-Week Low | $163.32 | $24.22 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Upstart Holdings (UPST) trades at $32.74, down 1.47% on the day, with a bullish technical signal and neutral oscillators. The company reported a return to profitability in 2025 with $53.60M net income on $1.02B revenue, though recent quarterly earnings missed expectations. Analyst consensus is mixed with a $42.00 price target, and the stock is positioned between key support at $32 and resistance at $34.
The outlook hinges on execution of AI lending growth and funding stability, with upside potential from product expansion, but risks include margin pressure, debt levels, and macroeconomic sensitivity. The stock offers a speculative growth opportunity amid improving fundamentals but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
